Literature DB >> 27370963

Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data.

Mirjana Bećarević1,2, Svetlana Ignjatović3,4.   

Abstract

The latest classification criteria for the diagnosis of the antiphospholipid syndrome (APS, an autoimmune disease characterized by thromboses, miscarriages and presence of antiphospholipid antibodies (Abs)) emphasized that thrombotic manifestations of APS should be without any signs of an inflammatory process. However, atherosclerosis (a chronic inflammatory response to the accumulation of lipoproteins in the walls of arteries) and APS are characterized by some similar features. We evaluated whether proinflammatory proteins were associated with the features of the primary APS (PAPS). PAPS patients without obstetric complications and with impaired lipid profile were included in the study. Antiphospholipid antibodies, TNF-alpha, and apo(a) were determined by ELISA. Complement components and hsCRP were measured by immunonephelometry. Decreased C3c was observed in female patients with increased titers of IgG anti-β2gpI (χ(2) = 3.939, P = 0.047) and in male patients with increased IgM anticardiolipin Abs (χ(2) = 4.286, P = 0.038). Pulmonary emboli were associated with interleukin (IL)-6 in male (χ(2) = 6.519, P = 0.011) and in female (χ(2) = 10.405, P = 0.001) patients. Cerebrovascular insults were associated with LDL-cholesterol (P = 0.05, 95 % CI: 1.003 - 12.739) in female and with apo(a) (P = 0.016, 95 % CI: 0.000-0.003) in male patients. Older female patients had increased LDL-cholesterol levels and frequency of myocardial infarctions. Proinflammatory proteins were associated with features of primary APS. No real gender differences in regard to proinflammatory protein levels were observed. Premenopausal state of female PAPS patients confers lower cardiovascular risk.

Entities:  

Keywords:  Antiphospholipid syndrome; Complement; High-sensitivity C-reactive protein; Interleukin 6; TNF-alpha

Mesh:

Substances:

Year:  2016        PMID: 27370963     DOI: 10.1007/s10067-016-3345-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

1.  High-sensitivity C-reactive protein: discriminator between patients with primary and secondary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Nada Majkić-Singh
Journal:  Clin Biochem       Date:  2008-09-04       Impact factor: 3.281

2.  High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk.

Authors:  E V Barnes; S Narain; A Naranjo; J Shuster; M S Segal; E S Sobel; A E Armstrong; B E Santiago; W H Reeves; H B Richards
Journal:  Lupus       Date:  2005       Impact factor: 2.911

3.  Anti-phospholipid antibodies contribute to arteriosclerosis in patients with systemic lupus erythematosus through induction of tissue factor expression and cytokine production from peripheral blood mononuclear cells.

Authors:  Yukari Motoki; Junzo Nojima; Masashi Yanagihara; Hidehiro Tsuneoka; Tomohiro Matsui; Misa Yamamoto; Kiyoshi Ichihara
Journal:  Thromb Res       Date:  2011-12-21       Impact factor: 3.944

Review 4.  The complement system in systemic autoimmune disease.

Authors:  Min Chen; Mohamed R Daha; Cees G M Kallenberg
Journal:  J Autoimmun       Date:  2009-12-11       Impact factor: 7.094

5.  Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study.

Authors:  P H Reitsma; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2004-04       Impact factor: 5.824

6.  Complement activation in patients with primary antiphospholipid syndrome.

Authors:  K Oku; T Atsumi; M Bohgaki; O Amengual; H Kataoka; T Horita; S Yasuda; T Koike
Journal:  Ann Rheum Dis       Date:  2008-07-14       Impact factor: 19.103

7.  Clinical spectrum of males with primary antiphospholipid syndrome and systemic lupus erythematosus: a comparative study of 73 patients.

Authors:  G Medina; O Vera-Lastra; L Barile; M Salas; L J Jara
Journal:  Lupus       Date:  2004       Impact factor: 2.911

8.  High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome.

Authors:  P R J Ames; E Matsuura; J R Batuca; A Ciampa; L L Lopez; F Ferrara; L Iannaccone; J Delgado Alves
Journal:  Lupus       Date:  2010-01-11       Impact factor: 2.911

Review 9.  Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?

Authors:  Ilaria Cavazzana; Nebuloni Manuela; Cetin Irene; Acaia Barbara; Saino Sara; Borghi Maria Orietta; Tincani Angela; Tedesco Francesco; Meroni Pier Luigi
Journal:  J Autoimmun       Date:  2007-04-06       Impact factor: 7.094

10.  Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study.

Authors:  Sverre C Christiansen; Inger Anne Naess; Suzanne C Cannegieter; Jens Hammerstrøm; Frits R Rosendaal; Pieter H Reitsma
Journal:  PLoS Med       Date:  2006-08       Impact factor: 11.069

View more
  9 in total

Review 1.  Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.

Authors:  Mirjana Bećarević
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

2.  Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Marija Sarić; Ljudmila Stojanovich; Duško Mirković; Violeta Dopsaj; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2018-06-12       Impact factor: 2.980

3.  Double positivity of the IgG isotype of both anticardiolipin and anti-β2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data.

Authors:  Mirjana Bećarević; Duško Mirković; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2016-10-14       Impact factor: 2.980

Review 4.  TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević
Journal:  Rheumatol Int       Date:  2016-10-04       Impact factor: 2.631

Review 5.  Adiponectin: a therapeutic target in the antiphospholipid syndrome?

Authors:  Mirjana B Bećarević; Božana S Nikolić; Svetlana D Ignjatović
Journal:  Rheumatol Int       Date:  2019-06-18       Impact factor: 2.631

Review 6.  Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha.

Authors:  Mirjana Bećarević
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

7.  Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies.

Authors:  Martina Fabris; Adriana Cifù; Cinzia Pistis; Massimo Siega-Ducaton; Desrè Ethel Fontana; Roberta Giacomello; Elio Tonutti; Francesco Curcio
Journal:  Auto Immun Highlights       Date:  2017-03-25

8.  Nephropathy in Pparg-null mice highlights PPARγ systemic activities in metabolism and in the immune system.

Authors:  Barbara Toffoli; Federica Gilardi; Carine Winkler; Magnus Soderberg; Laura Kowalczuk; Yvan Arsenijevic; Krister Bamberg; Olivier Bonny; Béatrice Desvergne
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

9.  Sex Differences in Clinical Characteristics and Prognosis in Primary Thrombotic Antiphospholipid Syndrome.

Authors:  Yongfa Huang; Huazhen Liu; Wanting Qi; Le Du; Mengtao Li; Xiaofeng Zeng; Xiaoxiao Guo; Jiuliang Zhao; Shuyang Zhang
Journal:  Front Cardiovasc Med       Date:  2022-07-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.